Autologous Cell Therapy Market Share, Size and Forecast 2028

Market Insights

• The global demand for autologous cell therapy was valued at USD 4518.9 Million in 2022 and is expected to reach USD 22617.48 Million in 2030, growing at a CAGR of 22.3% between 2023 and 2030.
• The mesenchymal stem cells segment is the market leader by cell type, accounting for more than 30% of total value in 2022, while the tumor-infiltrating lymphocytes segment is estimated to grow rapidly over the projection period.
• The cancer treatment application category is expected to expand rapidly in the forecast period, while the autoimmune diseases segment has the highest market share in 2022.
• The bone marrow source segment leads the global need for autologous cell therapy, accounting for more than 34% in 2022 and is predicted to expand at a high CAGR.
• The hospitals and clinics category dominated the market with 40% of the total revenue share by end-user. In contrast, the research institutes category will expand fastest over the projected time frame.
• North America is driving the rapid growth of the autologous cell therapy industry and accounted for more than one-third of the market in 2022, while Asia Pacific and Europe account for just under 54% of the market in 2022. In 2022, Europe had a market revenue share of more than 20%.
• Autologous cell therapies are being explored for various therapeutic applications, including cancer treatment, cardiovascular diseases, neurological disorders, and autoimmune diseases.
• The global autologous cell therapy market has been experiencing speedy growth in recent years, driven by advancements in regenerative medicine and cell therapy technologies.
• Autologous cell therapies are gaining traction in treating rare diseases, where personalized approaches can offer hope for patients with limited treatment options.

Executive Summary

Market Definition

The autologous cell therapy market encompasses the healthcare sector dedicated to developing, producing, and commercializing therapeutic approaches that employ a patient's cells, tissues, or biological materials for medical interventions. These innovative therapies involve collecting cells from the patient, their subsequent processing and modification outside the body, and the re-administration of these personalized treatments back to the same patient. Autologous cell therapies are employed to treat a diverse range of medical conditions, often capitalizing on the regenerative or immune-modulating properties of the patient's cells, promising tailored and potentially more effective treatments while minimizing the risk of immune rejection.

Market Overview

The global autologous cell therapy market has witnessed rapid growth in recent years and is expected to grow at a CAGR of 22.3% between 2023 and 2030. The market was valued at USD 4518.9 million in 2022 and is expected to reach USD 22617.48 million in 2030.

Autologous cell therapy is a unique treatment strategy that uses an individual's cells cultivated and expanded outside the patient's body before being reintroduced into the donor. It entails collecting, separating, and manipulating cells from the patient's body, generally from blood, bone marrow, or adipose tissue. This personalized treatment strategy has various advantages, including a lower chance of immunological rejection or unpleasant responses because the cells are genetically matched to the patient.

The autologous cell therapy market is expanding rapidly, owing to rising awareness of personalized medical treatments, advances in regenerative medicine, and expanding applications in various medical disciplines. This market is seeing large investments in research & development, contributing to the launch of novel therapies and technologies. The increased frequency of chronic diseases and the possibility for improved patient outcomes drive global demand for autologous cell therapies.

Segmentation by Cell Type

• The tumor-infiltrating lymphocytes (TILs) segment will exhibit the highest CAGR in the forecasted period. This upsurge can be attributed to the growing significance of TILs in cancer immunotherapy, particularly in treating melanoma and other solid tumors.
• The mesenchymal stem cells (MSCs) segment currently leads the market share, holding over 30% in 2022. MSCs, known for their regenerative potential and immunomodulatory properties, continue to dominate the market, with applications from orthopedic conditions to autoimmune diseases.

Segmentation by Application

• The autoimmune diseases segment is anticipated to achieve the highest CAGR over the projected period, driven by the growing prevalence of autoimmune disorders and the potential of autologous cell therapies in modulating the immune system.
• The cancer treatment segment is leading the market share with over 28% in 2022, underlining the substantial adoption of autologous cell therapies, particularly CAR-T cell therapies, in oncology.

Segmentation by Source

• The bone marrow segment remains dominant, satisfying more than 34% of the global demand for autologous cell therapy in 2022, with strong growth expectations. Bone marrow remains a rich source of various stem cells crucial for regenerative medicine.
• The adipose tissue segment offers an alternative source to ensure comprehensive coverage addressing the remaining therapeutic needs, with its accessibility and potential for diverse cell types.

Segmentation by End-User

• The research institutes segment is projected to witness the highest CAGR in the coming years, reflecting the importance of ongoing research and development efforts in advancing autologous cell therapy technologies and applications.
• The hospitals and clinics segment currently leads the global market share, holding over 40% in 2022, signifying the increasing clinical adoption of autologous cell therapies in mainstream healthcare.

Segmentation by Region

• North America stands out as a notably profitable region for industry players, accounting for over one-third of the share in 2022. A combination of advanced healthcare infrastructure, robust research initiatives, and a high prevalence of chronic diseases drives a strong regional market presence.
• Europe and Asia Pacific collectively contributed under 54% share in 2022. With over 20% share, Europe demonstrates a robust market presence due to its developed healthcare systems and significant investments in cell therapy research and development.
• The rest of the world, including Latin America, the Middle East, and Africa, fulfills the remaining demand for autologous cell therapy, with potential for growth as healthcare infrastructure and awareness continue to improve in these regions.

The increasing usage of such therapies in numerous industries like healthcare, regenerative medicine, and personalized medicine, as well as the rising need for innovative and effective treatment choices, are the primary drivers of growth in the global autologous cell therapy market.

In 2022, North America held the majority of the revenue share of the global autologous cell therapy market. The area benefits from a strong regulatory environment and healthcare infrastructure that encourage the creation and marketing of cutting-edge medical therapies. In addition, North America has been at the forefront of research and innovation in autologous cell therapy, with numerous academic institutions, biotechnology companies, and pharmaceutical firms actively engaged in research and clinical trials. The high prevalence of diseases such as cancer and cardiovascular disorders, coupled with a robust healthcare reimbursement system, has driven the adoption of autologous cell therapies in the region. For instance, the American Cancer Society's 2022 report predicts that approximately 1.9 million new cancer cases will be identified in the United States. Also, 80% of patients diagnosed with cancer in the US are 55 or older, and 57% are 65 or older.

Over the projection period, Asia Pacific is expected to be the fastest-growing region. The region features a rapidly expanding healthcare sector, with increasing investments in R&D and growing awareness of personalized medicine. Moreover, Asia Pacific has a large and diverse patient population, providing a substantial pool of potential candidates for autologous cell therapies. The favorable regional regulatory environment, improving healthcare infrastructure, and comparatively lower treatment costs attract local and international players, driving innovation and market expansion. The prevalence of certain diseases, such as cancer and diabetes, is rising in the region, further fueling the demand for advanced and personalized treatment options and positioning the region as a key growth hub in the autologous cell therapy market.

Key Highlights of the Report

The global autologous cell therapy market is segmented by cell type, application, end-user, source, and region. Mesenchymal stem cells are currently the dominant cell type, showcasing their versatility and regenerative potential. At the same time, the tumor-infiltrating lymphocytes segment is poised for remarkable growth, particularly within the context of immunotherapy applications. Cancer treatment, focusing on CAR-T cell therapies, leads the market in terms of application, underscoring the pivotal role of autologous cell therapies in oncology. Simultaneously, autoimmune diseases are projected to witness the highest growth, aligning with the need for immune modulation in treating autoimmune disorders. Bone marrow remains the primary source for autologous cell therapies, owing to its rich reservoir of hematopoietic stem cells and multipotent stromal cells. Hospitals and clinics currently serve as the dominant end-users, reflecting the increasing clinical adoption of autologous cell therapies.

The trend towards personalized medicines and targeted therapies has increased market demand for autologous cell therapy. This method improves treatment outcomes by utilizing a patient's cells, reducing the chance of rejection and increasing therapy efficacy. Technological advances in cell isolation, development and delivery techniques have dramatically enhanced the viability and scalability of autologous cell therapies. These improvements have enabled streamlined and standardized production procedures, making autologous cell therapies more accessible and cost-effective. The growing cases of chronic diseases such as cardiovascular disease, cancer, and autoimmune ailments has increased the need for novel therapeutic alternatives. Autologous cell therapies can also provide an upgraded response by utilizing the regenerative capacity of a patient's cells. However, factors such as higher treatment costs, complex manufacturing processes, and regulatory limitations can hinder the widespread adoption of these therapies. The limited availability of skilled professionals and specialized facilities for cell-based therapies also impedes market growth.

The North American region leads the global autologous cell therapy market, owing to the widespread use of cutting-edge healthcare technology. The United States, in particular, is a prominent contributor to regional market growth due to its highly advanced healthcare infrastructure and rising demand for personalized cell-based treatments. On the other hand, the Asia-Pacific is experiencing rapid growth in the autologous cell therapy industry, attributed to the increasing adoption of cell-based therapies in healthcare. The large regional population and the high prevalence of chronic diseases present significant opportunities for autologous cell therapy, specifically in countries like India, Japan, China, and South Korea.

What Are The Main Drivers Of The Global Autologous Cell Therapy Market?

The primary drivers of the global autologous cell therapy market include the growing demand for personalized medicine, particularly in the treatment of cancer and other complex diseases, as autologous cell therapies offer tailored solutions that align with an individual's genetic profile. Additionally, advancements in cell therapy technologies, such as CAR-T cell therapies, expanded applications of stem cells, and improved manufacturing processes, are expanding the market's potential. Increasing research and development investments, favorable regulatory initiatives, and rising patient awareness propel the market forward. Moreover, the continuous exploration of autologous cell therapies for a broader spectrum of medical conditions, including rare diseases and degenerative disorders, is expected to sustain the market's robust growth in the forecast period.

What Are The Major Challenges Faced By The Global Autologous Cell Therapy Market?

The global autologous cell therapy market encounters several significant challenges, including regulatory complexities surrounding the approval and manufacturing of personalized cell therapies, which can impede market expansion. Cost barriers associated with the intricate and often labor-intensive process of isolating and manufacturing patient-specific cells remain substantial, affecting accessibility and affordability. Besides, ensuring consistent quality control and standardization of production processes pose ongoing challenges, as does the need to address logistics and supply chain complexities, particularly for the timely and safe transportation of patient-derived cells. Market access issues stemming from variability in reimbursement policies across regions also impact the market, potentially limiting patient access to these innovative treatments.

What Are The Growth Opportunities In The Global Autologous Cell Therapy Market?

The global autologous cell therapy market presents promising growth opportunities driven by the increasing recognition of the potential of personalized medicine. Expanded applications beyond oncology, such as autoimmune diseases, cardiovascular disorders, and neurodegenerative conditions, offer a broader patient base and market reach. Advances in manufacturing technologies, like automation and scale-up capabilities, are poised to reduce production costs and improve the commercial viability of autologous cell therapies. Moreover, collaborations and partnerships among biotechnology firms, academic institutions, and healthcare providers fuel innovation and accelerate the development and commercialization of these therapies. The ongoing exploration of novel cell sources and innovative delivery methods also opens new therapeutic avenues, reaffirming the market's growth prospects over the upcoming years.

Market Drivers

Several factors drive the global autologous cell therapy market. The following are the key drivers of the global autologous cell therapy market:

Increased Personalized Medicines Demand

One of the primary drivers of the global autologous cell therapy market is the increasing demand for personalized medicine. Autologous cell therapies are uniquely tailored to individual patients, using the patient's cells, tissues, or biological materials. This level of personalization is particularly significant in cancer treatment, where therapies like CAR-T cell therapy are designed to target specific antigens on cancer cells, minimizing harm to healthy tissues and reducing side effects. Personalized treatments offer the potential for improved efficacy and address the growing preference for therapies that align with their genetic and medical profiles. This demand for personalized medicine drives investments, research, and clinical adoption of autologous cell therapies across various medical conditions.

The rising chronic disease prevalence and personalized medication demand will likely fuel market expansion over the forecast period. For example, the Food & Drug Administration (FDA) approved tisagenlecleucel (Kymriah) for individuals with certain forms of non-Hodgkin lymphoma in 2018, making it the second CAR T-cell therapy licensed for lymphoma. As a result, rising demand and adoption of personalized autologous cell treatments such as CAR-T are projected to propel market growth.

Market Restraints

The global autologous cell therapy market faces challenges that may hinder its growth. These include the following:

High Treatment Costs and Accessibility Barriers

One of the major restraints on the global autologous cell therapy market is the high cost associated with these treatments. Autologous cell therapies involve a complex and often labor-intensive process, including cell collection, isolation, expansion, modification, and reinfusion. Each process step requires specialized equipment and skilled personnel, contributing to substantial production costs. Additionally, the need for stringent quality control measures and regulatory compliance further adds to the expenses. Moreover, autologous cell therapies are often customized for individual patients, challenging economies of scale. Thus, these therapies can be prohibitively expensive for many patients, limiting their accessibility and affordability.

Opportunities

The global autologous cell therapy market offers significant growth opportunities. These include the following:

Emerging Therapeutic Modalities and Innovations

Continuous advancements in cell therapy technologies present a substantial opportunity for the autologous cell therapy market. Innovations in cell processing, gene editing, and manufacturing automation are enhancing the efficiency, scalability, and cost-effectiveness of producing personalized cell therapies. For example, the development of closed, automated systems for cell manufacturing minimizes contamination risks and reduces production costs. Furthermore, gene-editing tools like CRISPR-Cas9 enable precise and targeted modifications of patient-derived cells for therapeutic purposes, expanding the therapeutic potential of autologous cell therapies. These technological advancements improve the overall feasibility of these therapies and, attract investment, foster research, and encourage the development of novel treatments, ultimately promoting market growth.

Competitive Landscape

Key Players

The competitive landscape of the global autologous cell therapy market is characterized by intense rivalry among various industry players, including biotechnology companies, pharmaceutical firms, and academic research institutions. The following are some of the top market players and their market shares:

• BrainStorm Cell Therapeutics
• Pharmicell Co. Inc
• Opexa Therapeutics
• Caladrius Biosciences Inc
• U.S. Stem Cell Inc
• Lonza
• Bristol Myers Squibb
• Novartis
• Tego Science
• Corning Incorporated
• Bio Elpida
• Vericel Corporation
• Catalent Inc
• Sartorius AG
• Others

These players are vying for market share and technological leadership by investing heavily in research & development efforts to advance cell therapy platforms and manufacturing processes. Strategic collaborations, mergers, and acquisitions are commonplace, allowing companies to broaden their product portfolios, enhance manufacturing capabilities, and access a wider patient base. Regulatory compliance, stringent quality control, and adherence to evolving standards are critical factors in gaining a competitive edge. Moreover, the market's growth is fueled by the emergence of startups and smaller enterprises that bring innovation and novel therapeutic approaches, further intensifying competition in this dynamic and rapidly evolving sector.

In April 2022, TreeFrog Therapeutics announced The Stem Cell SpaceShot Grant, which will fund research in stem cell biology and regenerative medicine for USD 100,000.

In May 2020, Lonza and Noga Therapeutics teamed to develop autologous lentiviral gene therapy using the Cocoon Platform. This relationship assisted the company in bringing new autologous gene therapy for Primary Immune Deficiencies (PIDs) to the clinic and patients. This technique helped the corporation strengthen commercial relationships and expand its customer base.

Summary of Key Findings

• The autologous cell therapy market is expected to grow robustly, driven by increasing demand for personalized medicine and advancements in cell therapy technologies.
• Market segmented by cell type, application, end-user, source, and region.
• Stem cell-based therapies, especially those using mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs), dominate the autologous cell therapy market due to their versatility and potential for personalized treatments.
• Within the autologous cell therapy market, oncology applications, such as CAR-T cell therapies for lymphoma and leukemia, have gained significant traction and represent a substantial portion of the market.
• The high cost associated with autologous cell therapy procedures, including cell isolation and manufacturing, remains a key barrier to wider adoption.
• Ongoing advancements in manufacturing techniques, such as automation and scalable production processes, are streamlining the development and commercialization of autologous cell therapy products.
• Integrating autologous cell therapy with digital health platforms allows for real-time monitoring of patient outcomes, treatment efficacy, and adherence to therapy protocols.

Future Outlook

• Continued advancements in gene editing, cell expansion, and cryopreservation technologies are expected to improve the efficiency and scalability of autologous cell therapies.
• Biobanking facilities that store and manage patient-derived cells are seeing growth to support the storage and retrieval of cells for autologous therapies.
• Many clinical trials are ongoing worldwide, assessing the safety and efficacy of various autologous cell therapy approaches across different disease indications.
• A shift toward patient-centric healthcare will fuel the adoption of autologous cell therapies, aligning treatments with individual genetic profiles.

Segmentation

• By Cell Type
  • Mesenchymal Stem Cells
  • Chondrocytes
  • Dendritic Cells
  • Tumor-Infiltrating Lymphocytes
  • Others
• By Application
  • Cancer Treatment
  • Autoimmune Diseases
  • Cardiovascular Diseases
  • Musculoskeletal Disorders
  • Neurological Disorders
  • Others
• By End-User
  • Hospitals and Clinics
  • Research Institutes
  • Biotechnology and Pharmaceutical Companies
• By Source
  • Bone Marrow
  • Blood
  • Adipose Tissue
  • Skin
  • Other Tissues
• By Region
  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • The U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • South-east Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa

Adjacent Markets

Several adjacent markets have high revenue growth opportunities in the autologous cell therapy market. The key adjacent markets for autologous cell therapy market –

Advancements in Cell Therapy Technologies

Innovations such as CAR-T cell therapies, improved cell isolation, and scalable manufacturing processes are making autologous cell therapies more effective and commercially viable, driving broader adoption across multiple indications.

Rising Prevalence of Chronic and Complex Diseases

The increasing incidence of cancer, autoimmune, and cardiovascular diseases is fueling demand for personalized and regenerative treatment options, positioning autologous cell therapy as a preferred approach for conditions with limited conventional therapies.

Growing Demand for Personalized Medicine

Autologous cell therapies offer tailored treatments using a patient’s own cells, reducing the risk of immune rejection and improving efficacy, which aligns with the healthcare industry’s shift toward individualized care.

Expanding Clinical Applications and Research Investments

Significant investments in R&D and ongoing clinical trials are broadening the therapeutic scope of autologous cell therapies beyond oncology to include autoimmune, neurological, and musculoskeletal disorders, accelerating market growth.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.